Johnson & Johnson has just agreed to let the non-profit Stop TB Partnership develop and distribute generics of the drug bedaquiline, a drug for multi-drug-resistant/extensively drug-resistant tuberculosis. From Forbes:
Johnson & Johnson charges $272 for the total six-month course needed to treat tuberculosis, but one study published in 2017 estimated that if generics entered the market, the price would fall to somewhere between $48-$102.
In 2022, this paper modelled the incremental cost per DALY averted at 364 USD/DALY averted for patients in South Africa who had extensively drug-resistant tuberculosis.
Not sure how to do this math. Would this new deal with Stop TB Partnership change that estimate very much?